Notice: Function _load_textdomain_just_in_time was called incorrectly. Translation loading for the wordpress-seo domain was triggered too early. This is usually an indicator for some code in the plugin or theme running too early. Translations should be loaded at the init action or later. Please see Debugging in WordPress for more information. (This message was added in version 6.7.0.) in /var/www/html/wp-includes/functions.php on line 6260 Financial Reports: Biogen Idec 2Q11 | Contract Pharma

What are you searching for?

Sign in
Breaking News, Financial News

Financial Reports: Biogen Idec 2Q11

Tysabri revenues climb 28%

Author Image

By: Tim Wright

Editor-in-Chief, Contract Pharma

Biogen Idec 2Q

2Q Revenues: $1.2 billion (flat)

2Q Earnings: $304.0 million (+3%)

YTD Revenues: $2.4 billion (+4%)

YTD Earnings: $612.8 million (+19%)

Comments: Tysabri revenues were up 28% to $281 million in the quarter. Avonex sales were $659 million (+5%). Rituxan revenues from the joint partnership with Genentech were $216 million in the quarter, down 29% due to ongoing arbitration between Genentech and Hoechst GmbH. Revenues from other products were $16 million, up 36%. Royalties were $29 million in the quarter (-5%).

Add us as a preferred source on Google

Get the latest Contract Pharma news, insights and analysis in your Google Search and AI experiences.

Add Contract Pharma as a preferred source on Google (opens in a new tab)

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters